Key points are not available for this paper at this time.
Thrombolysis in patients >75 years warrants clinical caution; leaves open optimal reperfusion strategies pending prospective trials.
In nationwide clinical practice, thrombolytic therapy for patients >75 years old is unlikely to confer survival benefit and may have a significant survival disadvantage. Reperfusion research that is focused on elderly patients is urgently needed.
No takes yet. Share an insight, caveat, or question.
Thiemann et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: